The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cellular Therapy of Autoimmune Disease

Cellular Therapy of Autoimmune Disease

November 1, 2008 • By Alan Tyndall, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Cellular therapy refers to the use of live cells to replace or repair a damaged organ system. The first widespread use of this approach occurred more than 50 years ago when hematopoietic stem cells (HSCs) from the bone marrow of a healthy donor (allogeneic) were used to replace the hematopoietic system of a recipient after it was ablated during chemo/radio therapy of leukemia, the recipient’s hematopoietic system being “collateral damage” during the eradication of the unwanted leukemia cells.

You Might Also Like
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • HSCT for Severe Autoimmune Diseases
Explore This Issue
November 2008

This approach was later extended to the use of autologous stem cells in various malignant conditions such as breast cancer, allowing the use of more intense chemotherapy. In this context, the therapy is referred to as “hematopoietic stem cell support.” This principle was adopted for treating severe autoimmune disease more than 10 years ago in patients who failed to respond to conventional immunosuppression but in whom the marrow toxicity restricted dose escalation. Over 1,000 autoimmune disease patients have been treated, with around 30% achieving sustained remission.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recently another cell, the mesenchymal stem cell (MSC), has been applied to the treatment of autoimmune disease. The concept is completely different from HSC in that pretreatment with chemotherapy is not required, and the MSCs are thought to home in on damaged tissue and exert a local paracrine healing effect. This article will review the basis of this novel treatment and results of recent trials.

Adult Stem Cells

A typical adult stem cell is one which, on division, results in one daughter cell that can further differentiate and replenish a whole compartment or tissue, while the other remains fully “stem” and self-renewing. This is called asymmetric division, and the stem cell is known as multipotent. (See Figure 1, p. 21.)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The best-studied example of this type of adult stem cell is the hematopoietic stem cell, which produces a trillion differentiated blood cells per day for the life of the animal. This remarkable property is possible because of a complex interaction between the stem cell and other cells and structures within the bone marrow microenvironment called the niche. However, other stem cells exist in the embryo from the moment of conception; the first eight to 16 divisions produce totipotent stem cells by symmetrical division. The word totipotent is used here because each cell may produce a full individual animal because the placental elements are present. Identical twins are the best example. Once the blastocyst has formed with an inner cell mass (destined to become the fetus) and an outer membrane (the early placenta), then the embryonal stem cells (ESCs) from the inner cell mass are called pluripotent. This means that all organs and tissues may be produced but no longer an intact individual. (See Figure 2, p. 22.)

Recently, another cell, the mesenchymal stem cell (MSC), has been applied to the treatment of AD. The concept is completely different from HSC in that pretreatment with chemotherapy is not required, and the MSCs are thought to home in on damaged tissue and exert a local paracrine healing effect.

ESCs have extensive plasticity in terms of potential in vitro tissue differentiation, but they also carry an intrinsic risk of developing teratomas. In addition, the harvesting of pluripotent ESC requires destruction of an embryo, which raises ethical and theological issues limiting their utility.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 9 | Single Page

Filed Under: Conditions, Guidelines Tagged With: Autoimmune disease, Cellular Therapy, Research, TreatmentIssue: November 2008

You Might Also Like:
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • HSCT for Severe Autoimmune Diseases
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.